372 related articles for article (PubMed ID: 12112979)
1. Chemotherapy in epithelial ovarian cancer.
Wang J; Li AJ; Karlan BY
Curr Womens Health Rep; 2002 Feb; 2(1):20-6. PubMed ID: 12112979
[TBL] [Abstract][Full Text] [Related]
2. Advances in the management of epithelial ovarian cancer.
Berkenblit A; Cannistra SA
J Reprod Med; 2005 Jun; 50(6):426-38. PubMed ID: 16050567
[TBL] [Abstract][Full Text] [Related]
3. Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group.
Emons G; Ortmann O; Teichert HM; Fassl H; Löhrs U; Kullander S; Kauppila A; Ayalon D; Schally A; Oberheuser F
Cancer; 1996 Oct; 78(7):1452-60. PubMed ID: 8839551
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in the management of women with ovarian cancer.
Eltabbakh GH
Minerva Ginecol; 2004 Feb; 56(1):81-9. PubMed ID: 14973412
[TBL] [Abstract][Full Text] [Related]
5. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S;
J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344
[TBL] [Abstract][Full Text] [Related]
6. Medical treatment of epithelial ovarian cancer.
González-Martín AJ
Expert Rev Anticancer Ther; 2004 Dec; 4(6):1125-43. PubMed ID: 15606338
[TBL] [Abstract][Full Text] [Related]
7. [Multidisciplinary treatment of recurrent epithelial ovarian carcinoma and prognostic analysis].
Huang X; Cai SM; Tang J; Li ZT; Zang RY
Zhonghua Fu Chan Ke Za Zhi; 2004 Sep; 39(9):602-5. PubMed ID: 15498187
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy for advanced ovarian cancer: overview of randomized trials.
Thigpen JT
Semin Oncol; 2000 Jun; 27(3 Suppl 7):11-6. PubMed ID: 10952121
[TBL] [Abstract][Full Text] [Related]
9. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments.
Kyrgiou M; Salanti G; Pavlidis N; Paraskevaidis E; Ioannidis JP
J Natl Cancer Inst; 2006 Nov; 98(22):1655-63. PubMed ID: 17105988
[TBL] [Abstract][Full Text] [Related]
10. Bowel resection at the time of primary debulking for epithelial ovarian carcinoma: outcomes in patients treated with platinum and taxane-based chemotherapy.
Estes JM; Leath CA; Straughn JM; Rocconi RP; Kirby TO; Huh WK; Barnes MN
J Am Coll Surg; 2006 Oct; 203(4):527-32. PubMed ID: 17000397
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of epithelial ovarian cancer].
Langmár Z; Csömör S
Orv Hetil; 2006 Aug; 147(34):1627-32. PubMed ID: 17017677
[TBL] [Abstract][Full Text] [Related]
12. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
Ozols RF
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
[TBL] [Abstract][Full Text] [Related]
13. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer.
Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Aghajanian C; Barakat RR; Chi DS
Gynecol Oncol; 2008 Feb; 108(2):276-81. PubMed ID: 18063020
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and management of epithelial ovarian cancer.
Bhoola S; Hoskins WJ
Obstet Gynecol; 2006 Jun; 107(6):1399-410. PubMed ID: 16738170
[TBL] [Abstract][Full Text] [Related]
15. Second-line therapy for potentially platinum-sensitive recurrent ovarian cancer: what is optimal treatment?
Markman M
Gynecol Oncol; 2001 Apr; 81(1):1-2. PubMed ID: 11277641
[No Abstract] [Full Text] [Related]
16. First-line treatment of advanced ovarian cancer: current research and perspectives.
Marchetti C; Pisano C; Facchini G; Bruni GS; Magazzino FP; Losito S; Pignata S
Expert Rev Anticancer Ther; 2010 Jan; 10(1):47-60. PubMed ID: 20014885
[TBL] [Abstract][Full Text] [Related]
17. [The impact of the pathologist on the treatment of epithelial ovarial cancer].
Zivanovic O; Braun M; Park TW; Kuhn W
Verh Dtsch Ges Pathol; 2005; 89():101-10. PubMed ID: 18035679
[TBL] [Abstract][Full Text] [Related]
18. Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs.
Harter P; Hilpert F; Mahner S; Heitz F; Pfisterer J; du Bois A
Expert Rev Anticancer Ther; 2010 Jan; 10(1):81-8. PubMed ID: 20014888
[TBL] [Abstract][Full Text] [Related]
19. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer.
Milczek T; Klasa-Mazurkiewicz D; Emerich J; Kobierski J
Acta Obstet Gynecol Scand; 2009; 88(4):463-7. PubMed ID: 19235559
[TBL] [Abstract][Full Text] [Related]
20. Does secondary surgical cytoreduction improve survival in women with advanced ovarian cancer?
Munkarah A
Nat Clin Pract Oncol; 2005 Apr; 2(4):188-9. PubMed ID: 16264930
[No Abstract] [Full Text] [Related]
[Next] [New Search]